Ohio State University Comprehensive Cancer Center
🇺🇸United States
TAE Life Sciences and Ohio State University Partner to Advance Boron Neutron Capture Therapy for Cancer Treatment
TAE Life Sciences and Ohio State University have formed the first U.S.-based academic-industry alliance focused on developing novel boron-based drug compounds for Boron Neutron Capture Therapy (BNCT).
ACCC Fall 2024: Innovations in Clinical Trial Access, Patient Care, and Treatment Authorization
The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.
First-in-Human Trial Launched for Novel DHODH Inhibitor HOSU-53 in Solid Tumors and Lymphomas
A Phase I/II clinical trial is set to begin at Ohio State University, evaluating the novel DHODH inhibitor HOSU-53 in patients with advanced solid tumors and Non-Hodgkin's lymphoma.